乳腺癌HER2低表达共识达成的最佳实践:执业病理学家当前观点
本文由具有乳腺病理和乳腺癌生物标志物检测专长的执业病理学家撰写,阐述HER2低表达乳腺癌的IHC检测与评分现状及挑战,提出使用验证IHC检测评估HER2表达的算法,纳入2023年ASCO/CAP指南更新,并提供何时寻求共识、如何将HER2低表达纳入IHC报告及疑难病例示例的指导。
要点
- HER2低表达(IHC 1+或IHC 2+/ISH-)乳腺癌是靶向治疗相关类别。
- 推荐使用验证的IHC检测并按算法评估HER2表达。
- IHC报告应纳入HER2低表达状态并参考2023 ASCO/CAP更新。
核心结论
- 准确HER2 IHC评分对HER2低表达乳腺癌的最佳治疗选择至关重要。
研究设计与样本
- 执业病理学家基于现有知识与挑战提出最佳实践和指导。
主要发现
- 多数HER2阴性乳腺癌表达低水平HER2(IHC 1+或IHC 2+/ISH-)。
- HER2低表达是可采用新近获批HER2靶向抗体药物偶联物治疗的相关类别。
关键数值与推荐
- 提出使用验证IHC检测评估HER2表达的算法。
- 纳入2023年美国临床肿瘤学会和美国病理学家学院指南更新。
临床怎么用
- 使用验证IHC检测和算法准确识别HER2低表达乳腺癌。
- 将HER2低表达纳入IHC报告。
- 在需要时寻求HER2 IHC评分共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Human epidermal growth factor receptor 2 (HER2) expression is an important biomarker in breast cancer (BC). Most BC cases categorised as HER2-negative (HER2-) express low levels of HER2 [immunohistochemistry (IHC) 1+ or IHC 2+/in-situ hybridisation not amplified (ISH-)] and represent a clinically relevant therapeutic category that is amenable to targeted therapy using a recently approved HER2-directed antibody-drug conjugate. A group of practising pathologists, with expertise in breast pathology and BC biomarker testing, outline best practices and guidance for achieving consensus in HER2 IHC scoring for BC. METHODS AND RESULTS: The authors describe current knowledge and challenges of IHC testing and scoring of HER2-low expressing BC and provide best practices and guidance for accurate identification of BCs expressing low levels of HER2. These expert pathologists propose an algorithm for assessing HER2 expression with validated IHC assays and incorporate the 2023 American Society of Clinical Oncology and College of American Pathologist guideline update. The authors also provide guidance on when to seek consensus for HER2 IHC scoring, how to incorporate HER2-low into IHC reporting and present examples of HER2 IHC staining, including challenging cases. CONCLUSIONS: Awareness of BC cases that are negative for HER protein overexpression/gene amplification and the related clinical relevance for targeted therapy highlight the importance of accurate HER2 IHC scoring for optimal treatment selection.
引用
- Tozbikian G, Bui MM, Hicks DG, et al. Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists. Histopathology. 2024. PMID: 38973387. doi:10.1111/his.15275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。